Petco Health & Wellness Company, Inc. — Form 10-Q Summary
Reporting-period note: The request labels this “2023 Q1,” but the supplied filing is for the 13 weeks ended May 4, 2024, compared with the 13 weeks ended April 29, 2023. Figures below are in U.S. dollars; financial statement amounts have been converted from thousands to millions.
Business context and period
Petco operates an omnichannel pet products and services business, including more than 1,400 pet care centers, veterinary hospitals, grooming, digital channels, and Vital Care memberships. It reports one operating segment. The filing describes inflationary pressure and weaker discretionary spending as factors affecting results.
Financial results and liquidity
| Metric | 13 weeks ended May 4, 2024 | Prior-year period |
|---|---|---|
| Net sales | $1,529.1 million | $1,555.9 million |
| Gross profit / margin | $578.7 million / 37.8% | $604.5 million / 38.9% |
| Operating income (loss) | ($16.8 million) | $27.6 million |
| Net loss | ($46.5 million) | ($1.9 million) |
| Adjusted EBITDA / margin | $75.6 million / 4.9% | $111.0 million / 7.1% |
| Cash from operating activities | ($8.4 million) | $37.7 million |
| Free cash flow | ($41.1 million) | ($24.4 million) |
Cash and cash equivalents were $89.7 million at May 4, 2024. The company reported total liquidity of $617.3 million, including $527.6 million of ABL availability. The ABL facility had no borrowings outstanding; availability is subject to a borrowing base and includes the effect of $53.4 million of letters of credit.
Senior secured term-loan principal was $1,595.3 million, with a weighted-average interest rate of 8.9%. Total current and long-term debt carrying amounts were approximately $1,578.2 million, excluding operating lease liabilities. Total liabilities were $4,096.7 million. Operating lease liabilities totaled approximately $1,401.1 million.
Changes versus the prior comparable period
- Sales declined 1.7%; comparable sales fell 1.2%, versus growth of 5.1% in the prior-year quarter.
- Consumables sales were nearly flat at $764.0 million; supplies and companion animals declined 6.8% to $515.8 million. Services and other increased 4.2% to $249.4 million, with service-related sales up 10.5%.
- Gross margin contracted 1.1 percentage points. Management attributed the decline primarily to sales mix, including higher consumables and services and softer supplies sales.
- SG&A rose 3.2% to $595.4 million, increasing from 37.1% to 38.9% of sales. Management cited higher payroll and benefits, severance-related charges, occupancy costs, and depreciation.
- Adjusted EBITDA decreased by $35.4 million. Operating cash flow shifted from positive to negative, while capital spending was lower year over year.
Outlook, risks, and unusual items
- Management said current resources, anticipated operating cash flows, and ABL borrowing capacity are expected to fund operations and anticipated capital investments for at least the next 12 months. It cautioned that future financing may not be available on favorable terms or at all.
- In March 2024, Petco amended its ABL facility, increasing stated availability from $500 million to $581 million and extending maturity on a portion of the facility to March 29, 2029. The company reported compliance with debt covenants at May 4, 2024.
- Debt is variable-rate. The filing estimates that a 100-basis-point increase in variable rates would increase annual gross cash interest by approximately $16.2 million, before considering hedges. Interest-rate caps and collars hedge a portion of exposure.
- Operating cash flow was pressured by lower sales, inventory cash needs, and higher payroll and benefits, partly offset by lower lease payments and other working-capital effects.
- Petco recorded $3.5 million of fixed-asset and right-of-use-asset impairment charges, compared with $0.1 million in the prior-year period. No goodwill or trade-name impairment was recorded in the first quarter; the filing notes these valuations rely on significant estimates.
- Legal matters arise in the ordinary course. Management does not currently expect them to have a material adverse effect, but notes litigation outcomes are uncertain.
- The filing identifies risks involving consumer demand, competition, inflation and interest rates, vendors, supply chains, labor, cybersecurity and data privacy, payment processing and fraud, and execution of cost and operational initiatives.
- Disclosure controls were assessed as effective at a reasonable-assurance level; no material change in internal control over financial reporting was reported. The filing also includes an interim CEO employment letter and separation agreements, which investors may wish to review for leadership-transition context.
Important facts for investors to verify
- Confirm the period: the supplied filing is Q1 fiscal 2024, not Q1 2023.
- Review the trend in comparable sales, discretionary-category demand, services growth, and gross margin.
- Assess cash generation, capital spending, working-capital movements, and the ability to sustain liquidity as operating cash flow is negative.
- Verify debt maturities, borrowing-base availability, covenant headroom, variable-rate exposure, and the effectiveness and duration of hedges.
- Examine the drivers and recurrence potential of severance, impairment, acquisition-related, and other costs included in or excluded from Adjusted EBITDA.
- Review management’s leadership-transition disclosures and the assumptions supporting goodwill and trade-name valuations.